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Purpose: To investigate an association between the levels of serum thyroid-stimu-
lating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves’ orbitopathy 
(GO) activity/severity scores, and compare the performance of three different 
TRAb assays in assessing the clinical manifestations of GO. Materials and 
Methods: Cross-sectional study. Medical records of 155 patients diagnosed with 
GO between January 2008 and December 2010 were reviewed. GO activity was 
assessed by clinical activity score (CAS) and severity graded with the modified 
NOSPECS score by a single observer. Serum TRAb was measured by three differ-
ent methods: 1st generation thyrotropin-binding inhibitor immunoglobulin (TBII) 
assay (TRAb1st); 3rd generation TBII assay (TRAb3rd); and biological quantitative 
assay of thyroid-stimulating immunoglobulin (TSI) using Mc4-CHO cells (Mc4-
CHO TSI assay). Results were correlated with scores of activity/severity of thy-
roid eye disease. Results: All three assays (TRAb1st, TRAb3rd, and Mc4-CHO 
TSI) yielded results that were significantly positively correlated with CAS (β=0.21, 
0.21, and 0.46, respectively; p<0.05) and proptosis (β=0.38, 0.34, and 0.33, re-
spectively; p<0.05).  Mc4-CHO TSI bioassay results were significantly positively 
correlated with all GO severity indices (soft tissue involvement, proptosis, extraoc-
ular muscle involvement, and total eye score; β=0.31, 0.33, 0.25, and 0.39, respec-
tively; p<0.05). Conclusion: Mc4-CHO TSI bioassay was superior over the two 
TBIIs in assessing active inflammation and muscle restriction due to GO, whereas 
TBII assay would be sufficient for evaluation of patients with proptosis.
Key Words:   TSH-receptor autoantibody, Graves’ orbitopathy, disease activity, se-
verity
INTRODUCTION
Graves’ disease (GD) is a well-known multi-systemic autoimmune disorder. An 
autoantibody specific for thyroid-stimulating hormone receptor (TSH-R), which 
induces thyroid follicular cells to overproduce thyroid hormones, directly causes 
GD.1,2 Therefore, a test that specifically and sensitively detects TSH-R autoantibod-
ies (TRAb) is a very useful tool for diagnosis,3-6 patient follow-up,6-8 prediction of re-
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the Mc4-CHO cell line.13,17 
In the present study, we investigated whether a correlation 
existed between GO clinical features and TRAb as mea-
sured by the 1st and 3rd generation TBII assays, both of 
which are routinely used at our institution, as well as TSI as 
measured by a bioassay. The TSI bioassay used in our study 
uses a CHO cell line that is transfected with a Mc4 chime-
ric receptor. We also compared the performance of the three 
different TRAb assays in assessing the clinical features of 
thyroid eye disease. 
MATERIALS AND METHODS
　　　
Patients
Patients in this study were examined at the department of 
ophthalmology, Severance Hospital of Yonsei University 
College of Medicine between January 2008 and December 
2010. All subjects were diagnosed with GO and a single ob-
server (JSY) conducted follow-up of all patients. Diagnosis 
of GO was based on thorough clinical ophthalmic examina-
tion. The medical records of 168 patients with GO were re-
viewed and 13 patients were excluded because none of the 
three TRAb assays were performed. The medical records of 
the remaining 155 patients were retrospectively reviewed. 
Patient history, including diabetes, hypertension, any other 
autoimmune disorder, family history, smoking history, and 
type of treatment for GD were reviewed. GO activity was 
assessed using clinical activity score (CAS) as described by 
Mourits, et al.18 There were seven assessment items: spon-
taneous retrobulbar pain, pain on eye movement, eyelid ery-
thema, conjunctival injection, chemosis, swelling of the lac-
rimal caruncle, and eyelid edema or fullness. If the patient 
had any of these signs or symptoms, one point was assigned 
for each item, with a total possible score between 0 and 7 
points. GO severity was assessed by modified NOSPECS 
score and included soft tissue involvement, proptosis, and 
extraocular muscle (EOM) involvement. Each factor was 
separately graded and assessed, with the sum of the scores 
being equal to the total eye score (TES) (Table 1). The vi-
sion of each patient was checked and optic nerves were ex-
amined. If assessment revealed decreased vision and any disc 
swelling or pallor, or visual field defect or relative afferent 
pupillary defect (RAPD positive) was present, the patient 
was diagnosed with compressive optic neuropathy (ON). 
Each clinical measurement was performed at a consistent 
time following blood sampling and TRAb levels deter-
lapse,6 and GD treatment monitoring.8,9 Associated with 
Graves’ disease is Graves’ orbitopathy (GO), an inflammato-
ry condition affecting the orbit around the eye. The patho-
genesis of the ocular involvement of GD is explained by the 
expression of TSH-R not only in the thyroid follicular cells 
but also in adipocytes, fibroblasts, and lymphocytes in the or-
bit.1,10 Although the link between GD and GO is still un-
clear,11,12 the close association between onset of GD and the 
development of GO suggests that GD and GO may have 
common pathogenic mechanisms.1 Thus, the idea that 
TRAb detection may be of clinical benefit in the assessment 
of thyroid eye disease makes the elucidation of the relation-
ship between the autoantibodies and GO clinically valu-
able.11-15
Currently, the techniques measuring TRAb are broadly di-
vided into two categories: one is thyrotropin-binding inhibi-
tor immunoglobulin (TBII) assay and the other is a function-
al thyroid-stimulating immunoglobulin (TSI) bioassay.2 Since 
the development of TBII assay that quantifies serum TBII 
by exploiting the fact that the autoantibodies inhibit the 
binding of radiolabeled TSH to porcine thyroid membrane 
extract (1st generation TBII assay), many efforts have been 
made to improve this technique. These improvements to in-
crease the sensitivity of the test include replacing the por-
cine source of TSH-R with recombinant human TSH-R (2nd 
generation TBII assay); introduction and application of the 
human monoclonal thyroid-stimulating antibody M22 (la-
beled with biotin or ruthenium); and TSH-R coated ELISA 
plate well (3rd generation TBII assay)3-5,16 The TSI bioassay 
measures the production of cyclic adenosine mono-phos-
phate (cAMP) generated in response to the interaction be-
tween TSH-R and TSI.14,15,17 This method, therefore, en-
ables identification of the functional characteristics of TRAb. 
However, this test is complicated to perform and involves 
considerable time and cost.2 Additionally, labs conducting 
this test must be equipped to maintain and grow cell lines 
with tissue culture facilities. The TSI bioassay has also been 
significantly changed. Early versions of the bioassay mea-
sured the accumulation of 125I-labeled cAMP using a radio-
immunoassay (RIA) kit. Recently, the bioassay has used 
cAMP luciferase data as the endpoint. Compared to cAMP 
RIA, cAMP luciferase is advantageous due to the simplicity 
of the technique and superior sensitivity.17 Cell culture pro-
tocols have become much simpler and more effective over 
time, which is supported by the steady development of cell 
lines from a C6-18/wild type (wt) Chinese hamster ovary 
(CHO) cell line, to a K1/wt CHO cell line, finally creating 
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ry, and type of GD treatment, all of which may affect the 
clinical features of GO. An independent t-test was used to 
compare the mean autoantibody level between patients with 
and without ON. The statistical analyses were performed us-
ing SAS (SAS Institute Inc. v.9.1.3., Cary, NC, USA) and p-
value <0.05 was considered statistically significant. 
RESULTS
 
Among the 155 patients, TRAb1st, TRAb3rd, and TSI were 
used to measure serum autoantibodies in 113, 111, and 62 
patients, respectively. Mean subject age was 42.3±13.8 and 
the male/female ratio was 32 (20.6% male) : 123 (79.4% 
female). Demographic and serological data are shown in 
Table 2. Most patients with GD (88.4%) had been medically 
treated with antithyroid drugs and the majority of subjects 
were biochemically in euthyroid state (85.8%). The duration 
of GO was an 18.0±16.0 month (range: 2-84 months).
   
TRAb and TSI positively correlate with GO clinical 
activity and severity 
GO clinical activity was assessed using CAS and severity 
was assessed by modified NOSPECS score, including soft 
tissue involvement, proptosis, EOM involvement and TES.
Autoantibody levels measured by three different assays 
(TRAb1st, TRAb3rd, and Mc4-TSI bioassay) significantly 
positively correlated with both CAS (R=0.197, 0.200, 0.476, 
mined by all three assays were correlated with each clinical 
parameter.
Assays for TRAb detection
1st generation TBII assay (TRAb1st) was performed using 
the Assay for Thyrotropin Receptor Autoantibodies Kit from 
RSR Ltd. (Cardiff, UK) according to the manufacturer’s in-
structions. This kit consists of TSH receptor and 125I-labeled 
TSH. According to the manufacturer, this first generation 
assay is effective in detecting TRAb at concentrations ≥15 
international units (IU)/L. TRAb was also measured with 
the 3rd generation TBII assay (TRAb3rd) using the automat-
ed Cobas electrochemiluminescence (Elecsys, Roche Diag-
nostics GmbH, Penzberg, Germany). The cut-off value for 
positivity using this system was 1.75 IU/L.   
     
Cell-based TSI bioassay
Mc4-TSI in patient sera was measured with ThyretainTM TSI 
Reporter BioAssay (Diagnostic Hybrids, Inc., Athens, OH, 
USA) according to manufacturer instructions. The cells used 
for the assay were genetically engineered CHO cells, in which 
a chimeric human TSH-R (Mc4) was transfected. Amino ac-
ids 262-335 of the human TSH-R were replaced with amino 
acids 261-329 of the rat lutropin-choriogonadotropin receptor 
to form the chimeric human TSH-R. Patient sera were incu-
bated for approximately three hours with the CHO cell mono-
layer and any TSI present binded to the chimeric receptors 
on the cell surface. TSI/TSH-R binding induces activation 
of adenylate cyclase and triggers a signaling cascade result-
ing in increased intracellular cAMP. Intracellular cAMP 
then induces luciferase activity, which was measured as rel-
ative light units (RLU) detected by a luminometer in tripli-
cate wells. The resulting data was expressed as the speci-
men-to-reference ratio (SRR) percent, which was calculated 
with the following equation:
SRR%=[(Average Test RLU)/(average reference control 
RLU)]×100%
Results were considered positive when SRR ≥140% of 
the reference control.  
Data and statistical analysis 
The relationship between GO patient autoantibody titer and 
GO activity/severity was assessed using Pearson correlation 
analysis. Multivariate regression analyses were conducted 
using GO clinical manifestations as the dependent variables 
and autoantibodies as the independent variables. Factors 
adjusted for included age, sex, smoking history, past histo-
Table 1. Modified NOSPECS Score to Define Disease Sever-
ity 
Score NOSPECS classification
Soft tissue involvement with symptoms and signs
    0     Absent
    1     Minimal
    2     Moderate
    3     Severe
Proptosis
    0     <17 mm
    1     18-19 mm
    2     20-22 mm
    3     ≥23 mm
Extraocular muscle involvement
    0     Absent
    1     Limitation of motion at extreme gaze
    2     Evident restriction of motion
    3     Fixation of a globe or globes
Total eye score was the sum of soft tissue involvement, proptosis and 
extraocular muscle involvement score.
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or TRAb3rd. The results of both TBII assays (TRAb1st and 
TRAb3rd) and TSI were also positively correlated with pro-
ptosis (β=0.38, 0.34, and 0.33, respectively; p<0.05). The 
correlation coefficient between the results of the two TBII 
assays and proptosis were not different from that between 
the results of the TSI bioassay and proptosis. Interestingly, 
soft tissue and EOM involvement were positively correlat-
ed with only the TSI results (β=0.31, 0.25, respectively, p< 
0.05), and not the results of TRAb1st or TRAb3rd. TSI titers 
were significantly positively correlated with all clinical sever-
ity parameters, including TES (β=0.39, p<0.05) (Table 4).  
Vision and TSH-R autoantibodies
Compressive ON was diagnosed in 13 of the 155 patients 
(8.4%). Although no statistical significance was apparent 
between compressive ON and results of TRAb3rd and the 
TSI assay, patients with ON did have elevated autoantibod-
ies (Table 5). 
DISCUSSION
We investigated the relationship between TRAb levels as-
sessed by two types of assays [TBII (TRAb1st and TRA-
b3rd) and TSI bioassay] and GO activity/severity. Pearson 
correlation analyses determined that a significant correla-
tion existed between all the autoantibody levels in all three 
assays and both CAS (R=0.197, 0.200, and 0.476) and pro-
ptosis (R=0.413, 0.352, and 0.290). Multivariate regression 
analyses determined that TSI bioassay results were strongly 
positive correlated with all clinical scores of inflammatory 
activity and severity, including soft tissue involvement, pro-
ptosis, and myopathy. Importantly, the correlation coeffi-
cient between the TSI bioassay results and CAS (β=0.476) 
was more than 2-fold higher than those of the TRAb1st and 
TRAb3rd results (β=0.21 and 0.21, respectively), which 
supports the conclusion that the TSI bioassay is superior in 
assessing GO activity. Such strong relationship between 
TSI bioassay and GO activity was recently emphasized by 
Ponto, et al.19 The authors showed that all subjects with ac-
tive GO were TSI bioassay positive, whereas only 84% 
were TBII positive, and reported that chemosis was only 
ocular sign to predict TSI levels using multivariable regres-
sion analysis.19  
The TSI bioassay used in our study was the TSH-R lucif-
erase reporter bioassay with Mc4-CHO cells, which is a 
novel technique.17,20 In 2010, Lytton, et al.13 suggested that 
respectively; p<0.05) and proptosis (R=0.413, 0.352, 0.290, 
respectively; p<0.05). These correlations were determined 
by Pearson correlation analyses (Table 3). 
Possible confounders, such as age, sex, smoking history, 
underlying disorders, and GO treatment modality11,12 were 
adjusted for by multivariate regression analyses (Table 4). 
Regression analyses yielded significant positive correla-
tions between CAS and autoantibody levels measured by 
TRAb1st, TRAb3rd, and Mc4-TSI [regression coefficient 
(β)=0.21, 0.21, and 0.46, respectively; p<0.05] (Table 4). 
The correlation between the results of the TSI bioassay and 
CAS were stronger than those between CAS and TRAb1st 
Table 2. Demographic and Serological Data of Subjects En-
rolled in This Study 
Graves’ orbitopathy patients n=155
Age      42.3±13.8 (13-75)
Gender 123 females, 32 males
Smokers      33/155 (21.3%)
DM        8/155 (5.2%)
HTN      13/155 (8.4%)
Other autoimmune disease        6/155 (3.9%)
Family history of thyroid disease      28/155 (18.1%)
Therapy of Graves’ hyperthyroidism
    Anti-thyroid drugs    137/155 (88.4%)
    Radioiodine therapy        8/155 (5.2%)
    Thyroidectomy        5/155 (3.2%)
Peripheral thyroid function
    Euthyroid (without treatment)      31/155 (20%)
    Euthyroid (with ongoing treatment)    102/155 (65.8%)
    Hyperthyroid (although treatment)      22/155 (14.2%)
Duration of GO (months)       18.0±16.0 (2-84)
CAS of GO         2.0±1.7 (0-7)
TES of GO         3.0±1.9 (1-9)
Active GO (CAS ≥3)      53/155 (34.2%)
Sight-threatening GO      13/155 (8.4%)
Previous steroid therapy of GO      51/155 (32.9%)
Thyroid autoantibodies
    TRAb1st (unit/L)
  46.88±24.80 
    (2.96-100.00)
    TRAb3rd (IU/L)
  12.35±12.57 
    (0.33-40.00)
    TSI (SRR) %
429.90±211.21
  (54.20-1053.80)
CAS, clinical activity score; DM, diabetes mellitus; GO, Graves’ orbitopa-
thy; HTN, hypertension; SRR, specimen to reference ratio; TES, total eye 
score; TSI, thyroid-stimulating immunoglobulin.
TRAb1st: 1st generation thyrotropin-binding inhibitory immunoglobulin (TBII) 
assay. 
TRAb3rd: 3rd generation TBII assay. 
Data are presented as mean±standard deviation (range), unless otherwise 
indicated.
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CHO TSI bioassay were associated with all factors related 
to GO severity, including soft tissue involvement, propto-
sis, EOM involvement and TES (β=0.31, 0.33, 0.25, and 
0.39, respectively; p<0.05 by multivariate regression analy-
sis). Interestingly, we found that the correlation coefficients 
between the TBII assay results and proptosis (TRAb1st, 
β=0.38; TRAb3rd, β=0.34) were not different from that of 
the correlation between the TSI bioassay results and pro-
ptosis (β=0.33). As the key event in GO pathogenesis is the 
transference of orbital fibroblasts to adipocytes,1,21,22 the 
the results of the Mc4-CHO TSI bioassay are functional in-
dicators of GO activity and severity, as they yielded a stron-
ger positive correlation between TSI results and GO activi-
ty/severity. However, these authors assessed the relationship 
between TSI and GO severity only using the clinical severi-
ty score, which is equal to the sum of each severity class.13 
In the present study, we investigated GO severity with 
greater specificity by considering each subset of GO severi-
ty separately using a modified NOSPECS scoring system. 
Using this method, we found that the results of the Mc4-
Table 3. Pearson Correlation of TSH-Receptor Autoantibody (TRAb) Levels with Associated Clinical Manifestations of Graves’ 
Orbitopathy
TRAb1st TRAb3rd TSI (SRR) %
R p value R p value R p value
CAS    0.197*      0.036*   0.200*     0.034*   0.476*   <0.001*
Soft -0.085    0.369 0.097   0.310   0.290*     0.022*
Propto    0.413*   <0.001*   0.352*   <0.001*   0.290*     0.022*
EOM -0.065    0.491 0.111   0.244 0.271   0.090
TES  0.134    0.156   0.255*     0.007*   0.351*     0.005*
CAS, clinical activity score; EOM, extraocular muscle involvement; Propto, proptosis; R, correlation coefficient; Soft, soft tissue involvement; SRR, speci-
men to reference ratio; TES, total eye score; TSI, thyroid-stimulating immunoglobulin; TSH, thyroid-stimulating hormone.
TRAb1st: 1st generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay. 
TRAb3rd: 3rd generation TBII assay. 
*Significant p value (p<0.05 is considered statistically significant).
Table 5. Comparison of TSH-Receptor Autoantibody (TRAb) Levels between Graves’ Orbitopathy Patients With and Without 
Optic Neuropathy
TRAb1st TRAb3rd TSI Number
No ON (mean±SD) 47.40±24.54 11.76±12.10 416.62±197.31 142 (91.6%)
ON (mean±SD) 41.49±28.19 24.12±15.28 691.03±352.36 13 (8.4%)
p value* 0.536 0.077 0.309 155 (100%)
ON, optic neuropathy; SD, standard deviation; TSI, thyroid-stimulating immunoglobulin; TSH, thyroid-stimulating hormone.
TRAb1st: 1st generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay. 
TRAb3rd: 3rd generation TBII assay.
*Independent t-test was used for statistical analysis.
Table 4. Multivariate Regression Analyses of TSH-Receptor Autoantibody (TRAb) Levels and Clinical Manifestations of 
Graves’ Orbitopathy
TRAb1st TRAb3rd TSI (SRR) %
β p value* β p value* β p value*
CAS    0.21†    0.018†  0.21†    0.032† 0.46† <0.001†
Soft -0.05   0.552 0.10   0.270 0.31†   0.011†
Propto   0.38†  <0.001†  0.34†  <0.001† 0.33†   0.015†
EOM  0.01   0.918 0.16   0.051 0.25†   0.025†
TES  0.17   0.058  0.28†    0.002† 0.39†   0.002†
CAS, clinical activity score; EOM, extraocular muscle involvement; Propto, proptosis; β, regression coefficient; Soft, soft tissue involvement; SRR, speci-
men to reference ratio; TES, total eye score; TSI, thyroid-stimulating immunoglobulin; TSH, thyroid-stimulating hormone.
TRAb1st: 1st generation thyrotropin-binding inhibitory immunoglobulin (TBII) assay. 
TRAb3rd: 3rd generation TBII assay. 
*Adjusted for age, sex, smoking, underlying disease, hyperthyroidism treatment modality. 
†Significant p value (p<0.05 is considered statistically significant).
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